Abstracts tagged "Juvenile scleroderma"

Abstract Number: 023 • 2020 Pediatric Rheumatology Symposium
Capturing the Range of Disease Involvement in Localized Scleroderma: The Total Morbidity Score
Suzanne Li¹, Aashka Patel ², Elena Pope ³, Thomas Mason ⁴, Vidya Sivaraman ⁵, Fatma Dedeoglu ⁶, Kathryn Torok ⁷, Katie Stewart ⁸, Gloria Higgins ⁹, C. Egla Rabinovich ¹⁰, Robert Fuhlbrigge ¹¹, Maria Ibarra ¹², Sandy Hong ¹³, Polly Ferguson ¹⁴, Mara Becker ¹⁵, Brian Feldman ¹⁶ and Ronald Laxer ¹⁷ for the CARRA investigators, ¹Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, ²Hackensack University Medical Center, Hackensack, ³Hospital For Sick Kids, Toronto, Canada, ⁴Rochester, ⁵Division of Rheumatology, Nationwide Children's Hospital, Bexley, ⁶Boston Children's Hospital, Boston, ⁷Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, ⁸UT Southwestern, Dallas, ⁹Nationwide Childrens Hospital/ The Ohio State University, Columbus, ¹⁰Duke University Hospital, Durham, ¹¹University of Colorado, Aurora, ¹²Children's Mercy Kansas City, Kansas City, ¹³University of Iowa Stead Family Children's Hospital, Iowa City, ¹⁴University of Iowa Carver College of Medicine, Iowa City, ¹⁵Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, ¹⁶The Hospital for Sick Children, Toronto, Canada, ¹⁷The Hospital for Sick Children and University of Toronto, Toronto, Canada
Background/Purpose: Localized scleroderma (LS) is a chronic inflammatory and fibrosing disease that causes both cutaneous and extracutaneous (EC) damage. EC involvement (ECI) is common in…
Abstract Number: 024 • 2020 Pediatric Rheumatology Symposium
Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma
Suzanne Li¹, Sarah Ishaq ², Mary Buckley ³, Kathryn Torok ⁴, Barbara Edelheit ⁵, Kaleo Ede ⁶ and C. Egla Rabinovich ⁷, ¹Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, ²Montclair State University, montclair, ³Duke University, Durham, ⁴Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, ⁵CT Children's Medical Center, Hartford, ⁶Phoenix Children's Hospital, Phoenix, ⁷Duke University Hospital, Durham
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…
Abstract Number: 025 • 2020 Pediatric Rheumatology Symposium
HLA Genetic Signatures Associated with Inflammatory Sub-type in Juvenile Localized Scleroderma
Christina Schutt¹, Emily Mirizio ², Kaila Schollaert-Fitch ² and Kathryn Torok ², ¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease of the skin and underlying tissue that is characterized by an earlier inflammatory infiltrate, followed by…
Abstract Number: 078 • 2020 Pediatric Rheumatology Symposium
Reliability and Validity of a New Skin Activity Measure for Localized Scleroderma
Suzanne Li¹, Mara Becker ², Sandy Hong ³, Polly Ferguson ⁴, Themba Nyrienda ⁵, Tracy Andrews ⁶, Katie Stewart ⁷, C. Egla Rabinovich ⁸, Robert Fuhlbrigge ⁹, Thomas Mason ¹⁰, Elena Pope ¹¹, Maria Ibarra ¹², Fatma Dedeoglu ¹³, Gloria Higgins ¹⁴, Ronald Laxer ¹⁵, Marilynn Punaro ¹⁶ and Kathryn Torok ¹⁷ for the CARRA investigators, ¹Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, ³University of Iowa Stead Family Children's Hospital, Iowa City, ⁴University of Iowa Carver College of Medicine, Iowa City, ⁵Hackensack Univesity Medical Center, Hackensack, ⁶Rutgers University, Newark, ⁷UT Southwestern, Dallas, ⁸Duke University Hospital, Durham, ⁹University of Colorado, Aurora, ¹⁰Rochester, ¹¹Hospital For Sick Kids, Toronto, Canada, ¹²Children's Mercy Kansas City, Kansas City, ¹³Boston Children's Hospital, Boston, ¹⁴Nationwide Childrens Hospital/ The Ohio State University, Columbus, ¹⁵The Hospital for Sick Children and University of Toronto, Toronto, Canada, ¹⁶Dallas, Texas, ¹⁷Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh
Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic inflammatory and fibrosing disease. Treatment is directed towards controlling disease activity to minimize risk for functional impairment…
Abstract Number: 771 • 2019 ACR/ARP Annual Meeting
Von Willebrand Factor Is Localized in the Extravascular Tissue of Patients with Juvenile Scleroderma
Natalia Vasquez-Canizares¹, Beamon Agarwal ², Tamar Rubinstein ³, Dawn Wahezi ⁴ and Morayma Reyes Gil ⁵, ¹Children's Hospital at Montefiore, Bronx, NY, ²GenomeRxUS LLC, Providence, PA, ³Children's Hospital at Montefiore/Albert Einstein College of Medicine, Bronx, NY, ⁴Children’s Hospital at Montefiore, New York, ⁵Montefiore Medical Center/Albert Einstein College of Medicine, Bronx
Background/Purpose: Von Willebrand Factor (VWF) is a glycoprotein synthesized in endothelial cells and megakaryocytes that has an essential role in primary hemostasis. There is increasing…
Abstract Number: 776 • 2019 ACR/ARP Annual Meeting
Genetic Signatures Support Inflammation Driven Fibrosis in Localized Scleroderma
Christina Schutt¹, Emily Mirizio ², Claudia Salgado ³, Miguel Reyes-Mugica ³, Kaila L. Schollaert ² and Kathryn Torok ³, ¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, ³UPMC Children's Hospital of Pittsburgh, Pittsburgh
Background/Purpose: Localized scleroderma (LS) is a progressive autoimmune disease of the skin and underlying tissue that is characterized by an initial inflammatory infiltration which is…
Abstract Number: 791 • 2019 ACR/ARP Annual Meeting
Closing the Seronegative Gap in Pediatric Localized Scleroderma and Systemic Sclerosis
May Choi¹, Emily Mirizio ², Fernanda Quinteros ³, Katherine Buhler ⁴, Marvin Fritzler ¹ and Kathryn Torok ⁵, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²University of Pittsburgh, Pittsburgh, ³University of Calgary, Calgary, ⁴University of Calgary, Calgary, Canada, ⁵UPMC Children's Hospital of Pittsburgh, Pittsburgh
Background/Purpose: It has become increasingly recognized that extra-cutaneous manifestations, such as musculoskeletal and neurologic involvement, are common in pediatric patients with localized scleroderma (LS). We…
Abstract Number: 792 • 2019 ACR/ARP Annual Meeting
Speckle Tracking Echocardiography, a Sensitive Tool to Detect Early Cardiac Dysfunctions in Juvenile Systemic Sclerosis
Giovanni Civieri ¹, Biagio Castaldi ¹, Giorgia Martini ¹, Alessandra Meneghel ¹, Ornella Milanesi ¹ and Francesco Zulian², ¹Dept. of Woman's and Child's Health, university of Padua, Italy, Padua, Italy, ²Department of Woman and Child Health, University of Padua, Italy, Padova, Italy
Background/Purpose: Juvenile Systemic Sclerosis (JSSc) is a rare connective tissue disease in which cardiac involvement is burdened by high morbidity and mortality. The traditional cardiac…
Abstract Number: 1281 • 2017 ACR/ARHP Annual Meeting
Plasma CXCL4 As a Biomarker in Juvenile Systemic Sclerosis
Katharine Moore^1,2, Marvin J. Fritzler³, Marisa S. Klein-Gitelman⁴, Ann M Reed⁵, Tzielan Lee⁶ and Anne Stevens^7,8, ¹Pediatrics, University of Colorado, Aurora, CO, ²Pediatric Rheumatology, Children's Hospital Colorado, Aurora, CO, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴Division of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/Northwestern University, Chicago, IL, ⁵Rheumatology, Duke University, Durham, NC, ⁶Pediatric Rheumatology, Stanford University, Palo Alto, CA, ⁷University of Washington, Department of Pediatrics, Seattle, WA, ⁸Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: Juvenile systemic sclerosis (jSSc) is a severe and heterogeneous autoimmune vasculopathy. Pulmonary fibrosis is the highest independent predictor of mortality, yet currently there are…
Abstract Number: 2390 • 2016 ACR/ARHP Annual Meeting
Proposal of Assessment of the Activity of Juvenile Localised Scleroderma. Results of the Consensus Meeting in Hamburg, Germany December 2015
Ivan Foeldvari¹, Eileen Baildam², Michael Blakley³, Christina Boros⁴, Kim Fligelstone⁵, Antonia Kienast¹, Dana Nemkova⁶, Clare Pain², Amanda Saracino⁴, Gabriele Simonini⁷, Kathryn S. Torok⁸, Lisa Weibel⁹ and Nicola Helmus¹, ¹Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ²Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ³Internal Medicine and Pediatrics, Indiana University School of Medicine and Riley Hospital for Children at IU Health, Indianapolis, IN, ⁴Pediatric Rheumatology, London, United Kingdom, ⁵Manchester Academic Health Science Centre, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁶Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, ⁷Pediatric Rheumatology, Anna Meyer Children's Hospital, Florence, Italy, ⁸Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁹Pediatric Dermatology, University Childrenxs Hospital, Zurich, Switzerland
Background/Purpose: Juvenile Localised Scleroderma (JLS) is an orphan disease which is complicated by difficulties in robust measurement of disease activity. Several outcome measures to assess…
Abstract Number: 420 • 2015 ACR/ARHP Annual Meeting
Description of the Juvenile Localized Scleroderma Subgroup of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Eveline Y. Wu¹, Suzanne C. Li², Kathryn S. Torok³, Yamini Virkud⁴, Robert C. Fuhlbrigge⁵, C. Egla Rabinovich⁶ and CARRA Registry Investigators, ¹Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Pediatrics, Hackensack University Medical Center, Hackensack, NJ, ³Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ⁴Pediatrics, Massachusetts General Hospital for Children, Boston, MA, ⁵Pediatric Rheumatology, Boston Children's Hospital, Boston, MA, ⁶Pediatric Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: Localized scleroderma (LS) is a chronic inflammatory and fibrosing skin disease. We present baseline data on the juvenile LS (jLS) cohort from the Childhood…
Abstract Number: 424 • 2015 ACR/ARHP Annual Meeting
Magnetic Resonance and Echocardiographic Strain Rate Imaging for the Early Detection of Cardiac Involvement in Juvenile Systemic Sclerosis
Francesco Zulian¹, Marta Balzarin¹ and Elena Reffo, Biagio Castaldi, Giorgia Martini, Alessandra Meneghel, Ornella Milanesi, ¹Department of Pediatrics, University of Padua, Padua, Italy
Background/Purpose: Cardiac involvement is one of the worst prognostic factors in JSSc. The diagnosis is usually based on clinical symptoms, EKG and conventional echocardiography, but…
Abstract Number: 2178 • 2013 ACR/ARHP Annual Meeting
Juvenile Onset Systemic Sclerosis: Clinical and Serological Features, and Mortality In Comparison With Adult Onset Disease
Juan G. Ovalles-Bonilla¹, Francisco Javier López-Longo², Indalecio Monteagudo¹, Esperanza Naredo¹, Carlos Gonzalez Fernandez¹, María Montoro Alvarez¹, Lina Martínez-Estupiñán¹, Juan C. Nieto³, Julia Martínez-Barrio¹, Michelle Hinojosa¹, Natalia Bello¹, Belen Serrano¹, Carmen Mata¹ and Luis Carreño¹, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Hospital General Universitario Gregorio Marañón, Department of Rheumatology, Madrid, Spain, ³Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Currently data regarding long-term outcome of juvenile systemic sclerosis (jSSc) is scarce. To describe the differences between patients with jSSc versus adult onset evaluated at a single medical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].